DRAWINGS

Fig. 1




Fig. 2



SphI:11112
pUC ori
syn.poly(A)
SV40 ori
TOP1MARII+
CBX3C-UCOE
CMV enhancer
hE2F1a promoter
zeocin-R
SV40 poly(A)
HTLV R-U5'
WPRE
pTX7z-HIgG1L-#35
(11381 bp)
EF1-intron
SalI:8092
Puro-R
VL
EcoRI:3511
P2A
CL
EGFP
IRES
MluI:7420
VH
IRES
Hinge-Fc
EcoRI:4269

Fig. 3



3.5
3
2.5
2
1.5
1
0.5
0
Absorbancee at 450nm
1
2
3
4
5
6
7
8
9
Dilution log2

Fig. 4



(A)
Pancreas
Cancer adjacent pancreas tissue
Cripto-1 #35
negative control
(a)
(b)
(c)
(B)
Thymus gland
Thymus gland carcinoma, Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(C)
Prostate
Adenocarcinoma (Gleason grade:4), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(D)
Stomach
Adjacent normal gastric tissue (chronic atrophic inflammation of gastric body)
Cripto-1 #35
negative control
(a)
(b)
(c)

Fig. 5



(A)
Stomach
Cancer adjacent gastric tissue (chronic atrophic inflammation with intestinal metaplasia of gastric antrum)
Cripto-1 #35
negative control
(a)
(b)
(c)
(B)
Stomach
Mucous adenocartinoma(IIA), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(C)
Cervix
Squamous cell carcinoma (IIA, Malignant)
Cripto-1 #35
negative control
(a)
(b)
(c)
(D)
Cervix
Squamous cell carcinoma (IB, Malignant)
Cripto-1 #35
negative control
(a)
(b)
(c)

Fig. 6



(A) Cervix
Cancer adjacent cervix tissue (chronic cervicit is with atypical hyperplasia)
Cripto-1 #35
negative control
(a)
(b)
(c)
(B) Colon
Adenocarcinoma(IIB), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(C) Cervix
Squamous cell carcinoma (IIA, Malignant)
Cripto-1 #35
negative control
(a)
(b)
(c)
(D) Breast
Invasive ductal cartinoma(IB), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)

Fig. 7




3.5
3
2.5
2
1.5
1
0.5
0
U251MG
U251MG-SC1
SOX2
C-MYC
OCT3/4
KLF4
NANOG

Fig. 8


0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1/1280
1/640
1/320
1/160
1/80
1/40
1/20
1/10
1/5